Neurocrine Biosciences Reports Q1 2026 Earnings Exceeding $800 Million in Net Product Sales
Neurocrine Biosciences (NBIX) reported net product sales exceeding $800 million for the first time, driven by strong performance from INGREZZA and Cranesity. The company reaffirmed its full-year revenue guidance of $2.7 billion to $2.8 billion.
Tickers: $NBIX
Topics: Cranesity INGREZZA pharmaceuticals R&D pipeline sales growth